With a market capitalization (market cap) of $2.67B — a measure of how much the company is worth — Trevi Therapeutics, Inc. is the 1903rd most valuable company in Healthcare as of August 18, 2026. Shares trade at $18.84, up +1.95% on the day.
of 2,587
price ÷ annual EPS
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the advancement and commercialization of Haduvio, a potential treatment for debilitating neurologically mediated conditions. This orally administered, extended-release formulation of nalbuphine is currently undergoing Phase IIb/III clinical trials for chronic pruritus (severe itching) and persistent cough experienced by patients with idiopathic pulmonary fibrosis. Trevi Therapeutics also possesses a licensing agreement with Endo Pharmaceuticals Inc., granting it the rights to develop and market products containing nalbuphine hydrochloride in various formulations. Established in 2011, the company maintains its corporate headquarters in New Haven, Connecticut.
Visit websiteAs of August 18, 2026, Trevi Therapeutics, Inc. (TRVI) is worth $2.67B — this is its market capitalization, the total value of all its outstanding shares.
Trevi Therapeutics, Inc.’s market cap is $2.67B, which ranks it #1903 among the most valuable companies in the Healthcare sector tracked on MarketCapLens.
Trevi Therapeutics, Inc. (TRVI) shares trade at $18.84, up 1.95% on the day, as of August 18, 2026.
Fundamentals are annual. Figures labeled with their fiscal year.
FY 2025